Phase 2b/3 Study Shows Promise of SP-624 for Improving Depression, Cognition
SP-624, a SIRT6 activator, showed promise in a Phase 2b/3 study for treating depression and cognition in females with MDD. Positive EEG data suggests enhanced neural connectivity.